Delegates from European institutions and industry representatives unpacked the many challenges of improved access to critical medicines on the continent in a session at this year’s European Health Forum.
Stakeholders from different corners of the pharmaceutical industry and European institutions displayed their often-opposing views on how to solve the issue of improved access to critical medicines as part of a 26 September session at the European Health Forum in Bad Hofgastein, Austria.
Held in the popular ski destination Bad Hofgastein in Austria’s St
As financial volatility continues in the industry, Biocon’s board is considering merging its two off-patent drug businesses.
Viatris continues to make progress on remediation at the firm’s stricken manufacturing facility in Indore, India, following a warning letter and import alert delivered at the tail end of 2024.
A free trade agreement struck between the UK and India could over “significant benefits for the generic and biosimilar sectors,” Medicines UK believes. The off-patent industry association has also suggested further avenues for collaboration between the two governments on regulatory pathways and supply security.
